KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Vir Biotechnology (VIR) Accumulated Depreciation & Amortization (2018 - 2025)

Vir Biotechnology's Accumulated Depreciation & Amortization history spans 8 years, with the latest figure at $11.7 million for Q4 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization fell 19.77% to $11.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $11.7 million, a 19.77% decrease, with the full-year FY2025 number at $11.7 million, down 19.77% from a year prior.
  • Accumulated Depreciation & Amortization hit $11.7 million in Q4 2025 for Vir Biotechnology, up from $8.8 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for VIR hit a ceiling of $19.5 million in Q4 2023 and a floor of $1.5 million in Q2 2022.
  • Historically, Accumulated Depreciation & Amortization has averaged $9.3 million across 5 years, with a median of $9.6 million in 2023.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: plummeted 87.79% in 2022 and later surged 835.75% in 2023.
  • Tracing VIR's Accumulated Depreciation & Amortization over 5 years: stood at $5.3 million in 2021, then increased by 28.51% to $6.8 million in 2022, then soared by 186.76% to $19.5 million in 2023, then decreased by 25.15% to $14.6 million in 2024, then fell by 19.77% to $11.7 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for VIR at $11.7 million in Q4 2025, $8.8 million in Q3 2025, and $5.8 million in Q2 2025.